HCG Healthcare Global Enterprises Q2 FY26 results (Jul–Sep 2025) and concall
HealthCare Global Enterprises Limited reported strong FY2025 results with revenue of ₹2,200 crores and EBITDA of ₹396 crores, demonstrating 15% and 18% CAGRs respectively over the last five years. The company successfully deleveraged its balance sheet, reducing net debt to EBITDA to 2.3x. HCG outlined a clear strategy for future growth, focusing on optimizing its existing network, brownfield and greenfield expansions, and improving profitability towards 21-22% EBITDA margins and 20%+ ROCE for mature centers.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 16.8%, net profit up 0.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 554 | 559 | 585 | 613 | 647 +17% |
| EBITDA | 102 | 88 | 106 | 108 | 123 +21% |
| Net profit | 21 | 8 | 7 | 6 | 21 +0% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
